$CARA, $DT - On our trading list with news today or analyst comments with our opinion & trade ideas.Wainwright reiterates $33 target on Cara after new drug filing. Dynatrace initiated with a Buy at BTIG.H.C. Wainwright reiterates $33 target on Cara after new drug filingH.C. Wainwright analyst Oren Livnat reiterates a Buy rating on Cara Therapeutics with a $33 price target after the company announced the submission of the new drug application for IV Korsuva for chronic kidney disease associated pruritus in hemodialysis patients. Given the "robust" Phase 3s and no approved alternatives for CKD-aP, the analyst sees high probability of approval, and projects a second half of 2021 launch by partner Vifor Fresenius. IV Korsuva will be a "very high" operating margin product, which makes the profit split to Cara, 50% in Fresenius centers, 60% in non-Fresenius centers, "extremely compelling," Livnat tells investors in a research note. The analyst projects Cara's IV Korsuva recognized revenue to start in 2022, and projects peak partner IV Korsuva U.S. end-sales of around $700M with peak Cara revenue over $300M, at 100% gross profit, like a royalty.Our Take: Cara offers a good entry point near $15 or lower. We would consider buy/writes and selling of naked puts. $CARA, Cara Therapeutics, Inc. / H1 Dynatrace initiated with a Buy at BTIGBTIG analyst Gray Powell initiated coverage of Dynatrace with a Buy rating and $56 price target. The analyst sees the company as a leader in application performance monitoring, or APM, with more room to grow. Powell adds that he expects the APM market to directly benefit in 2021 as companies increasingly invest in digital transformation initiatives in efforts to improve customers' e-commerce experiences.Our Take: They are currently in the right field for dealing with the Covid working from home types. Only risk here is what might happen after the virus has passed? Will work from home still be a thing?Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page. .